LAS VEGAS — In this Healio Video Perspective from Clinical Trials at the Summit, Arshad M. Khanani, MD, MA, FASRS, discusses the phase 2 ACUITY trial investigating privosegtor for neuroprotection in patients with optic neuritis. According to Khanani, privosegtor, also known as OCS-05 (Oculis), is “a neuroprotective candidate activating neurotrophic signaling pathways supporting
This phase 2b/3 trial follows new, positive 2-year data from the phase 2 ALTITUDE trial, in which sura-vec was well-tolerated in subjects with non-proliferative diabetic…
Make your diagnosis in the comments, and get the answer to last month’s mystery.
The U.S. health care landscape has had a major shift characterized by a sharp increase in costs since the passage of the Affordable Care Act…
SAN FRANCISCO — A new clinical practice guideline for primary aldosteronism emphasized screening all patients with hypertension.The Endocrine Society published its first update to the…
The ADAPT study will evaluate the safety and effectiveness of the Calibreye surgical system in up to 70 patients with refractory glaucoma.
Long-term blood pressure variability (BPV) has emerged as a risk factor for various health problems, including eye diseases, independent of blood pressure (BP) levels. Yet,…
Given the rising incidence of colorectal cancer — particularly among younger adults — and ongoing threats to preventive screening in the U.S., the need for…
Immune effector cell-associated neurotoxicity syndrome is a complication of chimeric antigen receptor T-cell therapy.The condition is characterized by neurologic symptoms, such as tremors, confusion, delirium,…
Rising health care costs and federal policy changes are driving up premium rates for the growing number of Americans covered by the Affordable Care Act,…
➤ First gene therapy treatment for macular telangiectasia type 2 performed outside of trial ➤ First patient enrolled in Phase 2b study of ocular micro…
